Read More Pharma Industry News Sarepta’s gene therapy marches on: UK clears continued dosing in Duchenne Phase 3 trial Find out how Sarepta Therapeutics is advancing Duchenne gene therapy with UK backing for its ENVISION trial of ELEVIDYS in non-ambulatory patients. byPallavi MadhirajuMay 21, 2025